If you think the $50k is the primary point of interest of in this announcement, you need to re-read the detail.
Overall it further confirms the extreme confidence they have in succeeding in phase 1 breast cancer trials.
Not that it should need to be said to placate the uniformed or nervous nellies, but it's further example of what is going on day-to-day at IBX other than specifically human trials.This is setting the foundation to be able to turn-up in front of big imaging and/or big pharma with a product that has proven multiple applications, without peer, in the biggest cancer markets in the world.
What's that worth? An eye-watering number, I assure you.
IBX Price at posting:
17.5¢ Sentiment: Hold Disclosure: Held
